SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased chatter as investors speculate on potential breakout momentum following recent technical price action and discussions surrounding its enterprise-grade infrastructure. The community remains polarized, with many bulls highlighting the project's quantum-resistant cryptography and long-term utility while others debate whether the current price levels represent a durable floor or a continued downtrend.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan D. Green on March 5, 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is gaining significant community attention as investors debate its potential as a strategic acquisition target amidst high short interest and aggressive share repurchases. Discussion is centered on its valuation relative to competitors, its operational shift toward an asset-light model through partnerships, and the anticipation surrounding upcoming earnings as a key indicator of margin and bookings growth.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is in the spotlight as investors digest its recent earnings performance and track progress across its expanding pipeline, specifically looking for sustained growth from new launches like Journavx and Casgevy. The community is actively debating the company's ability to maintain its market dominance in cystic fibrosis while successfully diversifying into pain management and gene-editing therapies.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class A

Berkshire Hathaway is trending as investors react to the historic leadership transition with Warren Buffett stepping down as CEO and handing the reins to Greg Abel. Community discourse reflects a mix of sentiment regarding the conglomerate's massive cash position, the future of its equity portfolio strategy, and ongoing discussions about whether the firm will pursue large-scale acquisitions or continue its recent trend of net equity sales.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Wireless, Broadband and Satellite Services, and Other. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The Other segment consists of legacy 5G Network and 5G Network deployment operations that will not be utilized in the Wireless segment’s Hybrid MNO business. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is experiencing significant volatility as investors weigh the company's massive stake in SpaceX against ongoing concerns over its debt obligations and the pending AT&T spectrum deal. While the community remains divided on whether the stock acts as a discounted proxy for SpaceX, many traders are closely watching for updates on debt interest payments and the finalization of major cash-inflow transactions.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is trending as investors bet on the imminent humanoid robotics wave, specifically focusing on its planned merger with Agility Robotics and its high-profile backing from companies like NVIDIA and Amazon. The community is actively discussing the potential for a low-float, asymmetric setup similar to other successful SPAC stories, while weighing the risks of the early-stage robotics sector against significant institutional interest.

Ethena

Ethena is capturing significant community attention as investors weigh its aggressive growth in the synthetic dollar market against ongoing concerns regarding token unlocks and regulatory pressure. Bullish sentiment is being driven by institutional accumulation and the potential for increased yield-sharing, though many participants remain cautious due to historical price volatility.

Themes ETF Trust - Leverage Shares 2X Long SPCX Daily ETF

Leverage Shares 2x Long SPCX Daily ETF

The SPCH 2x Long SpaceX Daily ETF is seeing intense volatility and high trading volume as investors aggressively scalp the stock alongside its underlying asset. Traders are actively debating the impact of upcoming lockup expirations and SpaceX's recent public market activity, often utilizing the leveraged fund for short-term momentum plays despite warnings about the risks of holding these vehicles overnight.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is currently facing intense community debate as investors weigh concerns over continued price depreciation against the potential for a technical turnaround driven by the Polkadot 2.0 upgrade and new supply cap initiatives. While skeptics highlight the token's prolonged downtrend and lack of immediate institutional demand, bulls continue to emphasize its core architecture, high developer activity, and anticipation of broader regulatory clarity as catalysts for long-term recovery.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is drawing investor attention as it heads into its Q4 earnings report, with the community closely tracking how resilient consumer spending and cross-border volumes will offset ongoing regulatory concerns regarding potential credit interest rate caps. Investors remain focused on Mastercard's ability to maintain its high-margin competitive edge and expand its value-added services amidst a broader market shift toward digital payment infrastructure and AI-driven commerce.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that Sonia Quaratino, EVP Chief Medical Officer of Innate Pharma, will participate in the panel...

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502 (NCT06781983), its proprietary Nectin-4 exatecan ADC. Preliminary data are expected by year-end and...

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company PR Newswire SAN FRANCISCO, June 2, 2026 Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2...

Outcome of Innate Pharmas 2026 Annual General Meeting

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) announced the voting results of its shareholders at the Annual General Meeting (AGM), which took place on May 21, 2026, in Marseille. All resolutions were voted. A total of 94 votes were cast out of a...

Innate Pharma to participate in the Jefferies Global Healthcare Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced...

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its business update and consolidated financial results for the quarter ending March 31...

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

Regulatory News: Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) releases its...

Innate Pharma (IPHA) Expected to Announce Quarterly Earnings on Wednesday

Innate Pharma (NASDAQ:IPHA) will be releasing its Q1 2026 TU earnings before the market opens on Wednesday, May 13. (View Earnings Report at...

Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announces that the Company will hold a conference call on Wednesday, May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT, to provide an update on business progress for the first quarter of 2026...

Innate Pharma (NASDAQ:IPHA) Shares Down 0.7% - Here's What Happened

Innate Pharma (NASDAQ:IPHA) Stock Price Down 0.7% - Here's Why...

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma - ADR

IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info